Search Results for "Invokana"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Invokana. Results 11 to 12 of 12 total matches.
See also: canagliflozin
Empagliflozin (Jardiance) for Heart Failure with Reduced Ejection Fraction
The Medical Letter on Drugs and Therapeutics • Nov 01, 2021 (Issue 1636)
,
have been published. Table 1. FDA-Approved Indications of SGLT2 Inhibitors
Canagliflozin (Invokana)
▶ Treatment ...
The sodium-glucose cotransporter 2 (SGLT2) inhibitor
empagliflozin (Jardiance – Boehringer Ingelheim)
has been approved by the FDA for a third indication: to
reduce the risk of hospitalization for heart failure (HF)
and cardiovascular death in patients with heart failure
with reduced ejection fraction (HFrEF), with or without
type 2 diabetes. The SGLT2 inhibitor dapagliflozin
(Farxiga) was approved for the same indication in
2020. Empagliflozin has been granted breakthrough
therapy designation for treatment of patients with
heart failure with preserved ejection fraction...
Drugs for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022 (Issue 1663)
Receptor Agonists
SGLT2 Inhibitors
Canagliflozin (Invokana)
Reduce risk of MACE in adults with type 2 ...
Diet, exercise, and weight loss can improve glycemic
control, but almost all patients with type 2 diabetes
require antihyperglycemic drug therapy. Treating to
a target A1C of <7% while minimizing hypoglycemia
is recommended to prevent microvascular complications
of diabetes (retinopathy, nephropathy, and
neuropathy). An A1C target of <8% may be appropriate
for some older patients.